{"entity":{"id":"mark-middleton","kind":"person","name":"Mark Middleton","aka":[],"tldr":"Medical oncologist who co-directs Oxford Cancer, the city-wide partnership between the University of Oxford and Oxford University Hospitals.","summary":"Mark Middleton is one of three Directors of Oxford Cancer, the network and partnership between the University of Oxford and Oxford University Hospitals NHS Trust, alongside Tim Elliott and Adam Mead, and he co-chairs its Governance Board. He is Head of the Department of Oncology, Professor of Experimental Cancer Medicine and a Consultant Medical Oncologist at the Oxford Cancer and Haematology Centre, working on early phase, melanoma and upper gastrointestinal cancer trials. He trained at Cambridge, Oxford and the Christie Hospital and has been chief or principal investigator on more than 100 trials.","asOf":"2026-09-10","links":[{"label":"Source: Oxford Cancer, Our Team","url":"https://www.cancer.ox.ac.uk/about/our-team"}],"tags":["leadership","clinician-scientist","medical-oncology","early-phase-trials"],"related":[],"cancers":["melanoma","gastric","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oxford-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Oxford Cancer (co-director with Tim Elliott and Adam Mead)","institutionId":"oxford-cancer","specialisms":["Experimental cancer medicine","Melanoma","Upper gastrointestinal cancer","Early phase trials"],"profiles":[{"label":"Department of Oncology profile","url":"https://www.oncology.ox.ac.uk/team/mark-middleton"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Middleton+MR%5BAuthor%5D"}],"papers":[{"title":"Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial","journal":"The Lancet Oncology","year":2018,"doi":"10.1016/s1470-2045(18)30332-2"},{"title":"A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer","journal":"Cancer","year":2018,"doi":"10.1002/cncr.31791"},{"title":"A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424","journal":"British Journal of Cancer","year":2018,"doi":"10.1038/bjc.2017.484"}],"orcid":"0000-0003-0167-1685"},"route":"/people/mark-middleton/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"institution":[{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"},{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","route":"/institutions/oxford-cancer/"}]}}